Clinical Trial Update: Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating donor lymphocyte infusion of T-cells genetically modified with an iCasp9 suicide gene for leukemia and myeloma; trial status terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myeloma

Drugs mentioned

• Donor lymphocyte infusion (DLI) of T-cells genetically modified with iCasp9 suicide gene

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-07-16